超支严重却未达成目标,IBM沃森或面临与世界**癌症研究机构解约

2017-02-21 雷锋网 雷锋网

一向风光的AI界明星IBM 沃森,近几日似乎有点烦。让我们先回到几年前。2013年10月,IBM宣布德克萨斯大学癌症中心MD Anderson正在使用IBM 沃森认知计算系统共同消灭癌症。即便在沃森陷入挫折时,MD Anderson也力挺这位“治癌新星”。可惜好景不长,日前MD Anderson宣布该项目暂停,并证实从去年年底开始,癌症中心已积极要求其他供应商投标,在未来工作中取代IBM 沃森。“

一向风光的AI界明星IBM 沃森,近几日似乎有点烦。

让我们先回到几年前。2013年10月,IBM宣布德克萨斯大学癌症中心MD Anderson正在使用IBM 沃森认知计算系统共同消灭癌症。即便在沃森陷入挫折时,MD Anderson也力挺这位“治癌新星”。

可惜好景不长,日前MD Anderson宣布该项目暂停,并证实从去年年底开始,癌症中心已积极要求其他供应商投标,在未来工作中取代IBM 沃森。“这对IBM来说是一个不舒服的时刻”,Forbes 记者Matthew Herper如是说。

据了解,解约的原因由德克萨斯大学的一位审计员给出,他在报告中指出,该项目超支6200万美元,但尚未达成目标。报告进一步解释:“本文所述结果不应被解释为对其系统在当前状态的科学基础或功能能力的意见。”我们或许可以理解为,(沃森)你或许还不错,可惜太能花钱了,这个家我当不了。

MD Anderson 的发言人称:

作为一个公共机构,我们决定去竞争市场看看行业的发展。

无论如何,家长里短,暂放一边。就目前来看,作为明星的沃森,似乎越来越像一个超级英雄,不仅能够诊断癌症、白血病,还能够让报税人受益。即便在沃森与MD Anderson刚合作的2013年就有很多人说“未来已经来了”,但真的来了么?

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1935386, encodeId=a2e81935386ff, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Oct 28 02:07:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489931, encodeId=c01e148993123, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514170, encodeId=705615141e0bf, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621479, encodeId=aa4e16214e921, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1935386, encodeId=a2e81935386ff, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Oct 28 02:07:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489931, encodeId=c01e148993123, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514170, encodeId=705615141e0bf, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621479, encodeId=aa4e16214e921, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=)]
    2017-02-23 tulenzi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1935386, encodeId=a2e81935386ff, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Oct 28 02:07:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489931, encodeId=c01e148993123, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514170, encodeId=705615141e0bf, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621479, encodeId=aa4e16214e921, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1935386, encodeId=a2e81935386ff, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Oct 28 02:07:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489931, encodeId=c01e148993123, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514170, encodeId=705615141e0bf, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621479, encodeId=aa4e16214e921, content=<a href='/topic/show?id=82519314a5' target=_blank style='color:#2F92EE;'>#IBM沃森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9314, encryptionId=82519314a5, topicName=IBM沃森)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d0520274481, createdName=yese, createdTime=Thu Feb 23 01:07:00 CST 2017, time=2017-02-23, status=1, ipAttribution=)]
    2017-02-23 yese

相关资讯

IBM沃森大力拓展医疗领域,6个新合作项目亮相

自上个月宣布推出“沃森健康部门”(Watson Health)以来,IBM一直忙个不停,陆续宣布了一系列关于其认知计算软件(沃森)在医疗保健市场的合作和部署项目。   其中大部分项目是在IBM近期于纽约召开的“沃森世界”研讨会(World of Watson)上宣布的,其中包括以下6项合作:     1. IBM沃森与梅奥诊所(Mayo Clinic